2

ABSTRACT.
Objective. Examine whether lung endothelial cells (EC) from patients with Systemic Sclerosis (SSc)-associated interstitial lung disease (ILD) express mesenchymal cell markers and gene transcripts indicative of the occurrence of endothelial to mesenchymal (EndoMT) phenotypic transition.
Methods. Lung tissues from 6 patients with SSc-associated pulmonary fibrosis were examined by histopathology and immunohistochemistry. Confocal laser microscopy was employed to assess the simultaneous expression of EC and myofibroblast molecular markers. CD31+/CD102+ EC were isolated from lung tissues from two patients with SSc-associated ILD and from two normal lungs and the expression of EC and mesenchymal cell markers and other relevant genes were analyzed by quantitative PCR, immunofluorescence microscopy and Western blots.
Results.
Immunohistochemistry showed cells expressing the CD31-specific EC marker in subendothelial, perivascular and parenchymal regions of lungs from patients with SSc-associated ILD. Confocal laser microscopy identified cells co-expressing endothelial and mesenchymal cell markers in SSc-associated ILD tissues but not in control lungs. CD31+/CD102+ EC isolated from SSc lung tissues displayed simultaneous expression of von Willebrand factor and -smooth muscle actin and expressed high levels of mesenchymal cell-specific genes (collagen I, collagen III and fibronectin), EC-specific genes (collagen IV and VE-cadherin), profibrotic genes (TGF-β and CTGF) and genes encoding EndoMT-related transcription factors (TWIST and SNAI2).
Conclusion. Cells co-expressing endothelial and mesenchymal cell-specific molecular markers are present in the lungs from patients with SSc-associated ILD. CD31+/CD102+ EC isolated from SSc-affected lungs expressed simultaneously mesenchymal and EC-specific transcripts.
INTRODUCTION.
Systemic Sclerosis (SSc) is a systemic autoimmune disease of unknown etiology characterized by progressive fibrosis of skin and multiple internal organs, and severe fibroproliferative vasculopathy affecting the microvasculature resulting in severe vessel narrowing or even complete obliteration (1) (2) (3) . The pathogenetic mechanisms responsible for the fibrotic process and the severe vascular alterations in SSc are complex and have not been fully elucidated (4) (5) (6) .
Numerous recent studies have demonstrated that activated myofibroblasts are the cells ultimately responsible for the exaggerated deposition of extracellular matrix (ECM) macromolecules in skin, the parenchyma of affected organs such as the lungs and the heart, and the subendothelial space of small and medium sized arteries in SSc (7) (8) (9) . The activated myofibroblasts are a unique class of mesenchymal cells characterized by specific biological functions including a motile phenotype, expression of α-smooth muscle actin (α-SMA), increased production of fibrillar collagens type I (COL1) and type III (COL3), and reduction in the expression of genes encoding ECM-degradative enzymes (9-11).
The activated myofibroblasts in fibrotic tissues emerge from several sources (12,13), including expansion of resident tissue fibroblasts (14) , migration and tissue accumulation of bone marrow-derived circulating fibrocytes (15, 16) , and from epithelial cells, pericytes, and Gli1-positive perivascular progenitor cells that have undergone transition to a mesenchymal phenotype (17) (18) (19) . More recently, it has been demonstrated that endothelial cells (EC) are also capable of undergoing a phenotypic change into mesenchymal cells in a process known as endothelial to mesenchymal transition or EndoMT (20) (21) (22) (23) . Although EndoMT was initially considered to occur only during cardiovascular embryonic development (24, 25) , accumulating 5 evidence indicates that this process occurs in various experimentally-induced models of tissue fibrosis (20) (21) (22) (23) (26) (27) (28) (29) , and may play a role in the pathogenesis of certain human fibrotic and vascular disorders (30) (31) (32) (33) (34) . However, the possibility that EndoMT might be an important source of the mesenchymal cells responsible for the fibroproliferative vasculopathy and the fibrotic process in SSc has not been considered until very recently (35) . Demonstration that EndoMT may participate in the generation of activated myofibroblasts in SSc would be of substantial value as it may provide an important and currently unexplored target for the development of novel disease-modifying therapeutic interventions for this currently incurable disease (35) .
Here, we provide immunohistological and confocal microscopy evidence demonstrating that cells displaying specific EC molecular markers are present in the subendothelial, perivascular and parenchymal regions of lungs from patients with SSc-associated interstitial lung disease (ILD) and that EC expressing myofibroblast-specific molecular markers can be identified in the endothelium and subendothelial space of small arteries of lungs from patients with SScassociated ILD. We further show that CD31+/CD102+ EC isolated from SSc-affected lungs produce numerous mesenchymal cell specific proteins and display the simultaneous expression of mesenchymal and EC-specific-transcripts. These observations provide strong support to the hypothesis that a population of activated myofibroblasts involved in the progressive intimal fibrosis, vascular occlusion and pulmonary fibrosis in SSc-associated ILD originate from lung EC through the EndoMT process. This novel mechanism may represent an important and novel therapeutic target for the severe and currently fatal complications of SSc -associated fibroproliferative vasculopathy and pulmonary fibrosis. Table I ) and from the two normal lungs employing a modification of previously published methods (38,39) as described previously (40) . Briefly, lung tissue samples were minced with a scalpel and enzymatically digested with clostridial collagenase (30 mg/100ml in 0.1% BSA, Worthington, Lakewood, NJ) at 37°C for 1h to obtain a single cell suspension. The isolated cell suspension was immunoprecipitated with CD45 microbeads (MilTenyi BioTec, Auburn, CA) to remove non-EC as described (39) . Following immunomagnetic removal of CD45+ cells, the remaining cells were then employed for EC isolation and purification employing immunomagnetic immunoselection with rabbit anti-human CD31 antibody followed by magnetic bead separation using goat anti-rabbit IgG-conjugated 8 microbeads (1:5, Miltenyi Biotec). The isolated CD31+ EC were cultured in EC culture medium (ScienCell Research Laboratories, Carlsbad, CA) containing 5% FBS, 100 U/ml penicillin and 100 µg/ml streptomycin in 2% gelatin pre-coated tissue culture dishes for 5-10 days. Following expansion, the cells were re-suspended and the EC were subsequently further purified employing a second immunologic separation using rabbit anti-human CD 102 antibody to obtain a highly purified preparation of CD31+/CD102+ EC. The purified CD31+/CD102+ EC were plated on 2% gelatin coated plastic dishes, their morphology assessed by phase contrast microscopy, and their EC phenotype confirmed by evaluating the cellular uptake of 1,1'-
MATERIALS AND METHODS.
Biomedical Technologies, Stoughton, MA) as previously described (40) . All studies were performed with cells in early passage (less than passage 5) to assure the preservation of their original phenotype.
Immunofluorescence staining. CD31+/CD102+ lung EC were seeded onto glass culture slides and were fixed with 3.7% formaldehyde and permeabilized with 0.1% Triton X-100 in PBS for 3 min. Slides were washed with PBS and blocked with PBS containing 1% BSA at room temperature for 1 h, and then they were incubated with primary antibodies against α-SMA 
RESULTS.
Clinical and demographic characteristics of SSc-associated ILD patients studied. The clinical features of the patients and normal controls whose lung tissues were studied are shown in Table I . None of the patients had clinical features of pulmonary arterial hypertension (PAH) at the time the tissue samples were obtained and all were tested for the presence of PAH employing transthoracic echocardiograms and right heart catheterizations which were normal.
One patient developed clinical PAH 10 months after the lung biopsy sample was obtained. Figure 1D .
Histopathology and immunohistology. All six lung tissue samples from the
Confocal laser microscopy.
Confocal laser microscopy showed co-localization of vWF with α-SMA in the endothelium and within the subendothelial compartment in all SSc-associated ILD 11 samples (Figures 2A-2C ). In contrast, samples from normal controls did not show any cells coexpressing the endothelial and mesenchymal cell markers. Furthermore, in contrast with control lungs (Figure 3A) , in SSc-lungs the EC layer of some vessels displayed areas of detachment from the vessel wall ( Figure 3B, arrow) and numerous vessels showed portions of vessel lumen denuded from endothelial lining (Figure 3B, arrowheads) . The endothelial layer in the SSc tissues also displayed very weak or absent CD31 staining ( Figures 3B, 3C, and 3D) compared with the very intense CD31 staining in the vessels in the control lungs ( Figure 3A) . 
DISCUSSION.
The generation of activated myofibroblasts, which are distinguished from quiescent resident fibroblasts by the initiation of expression of α-SMA and the increased production of fibrillar type I and type III collagens (9) (10) (11) , is a crucial mechanism in the development of tissue fibrosis in SSc (7-9). There are numerous sources of activated myofibroblasts (12,13), including TGF-β-induced fibroblast to myofibroblast phenotypic change of resident quiescent fibroblasts (14) , recruitment and activation of bone marrow-derived fibrocytes (15, 16) , and transition of epithelial cells , pericytes, and Gli1-positive perivascular progenitor cells into mesenchymal cells (17) (18) (19) . Recently, EndoMT has been recognized as an important mechanism in the generation of activated myofibroblasts involved in the development of several experimentally-induced animal models of fibrotic diseases (20) (21) (22) (23) (26) (27) (28) (29) and may also play a role in some fibrotic human diseases (30) (31) (32) (33) (34) . EndoMT is a complex biological process during which EC lose their specific endothelial characteristics and the expression of EC-specific molecular markers such as VE-cadherin/Cdh5, PECAM1/CD31, ICAM2/CD102, and vWF, and concomitantly acquire the upregulated expression of α-SMA as well as that of mesenchymal cell-specific components such 13 as fibrillar type I and type III collagens. The detailed mechanisms involved in EndoMT have not been fully elucidated, although the crucial role of TGF-β in its initiation and maintenance, as well as the participation of several transcription factors involved in cellular transdifferentiation including SNAI1, SNAI2 or SLUG, and TWIST1 has been well documented (20) (21) (22) (23) (42) (43) (44) .
Despite the extensive experimental evidence supporting a role of EndoMT in the pathogenesis of tissue fibrosis there have been some reports raising controversy as to whether EndoMT was indeed a source of activated myofibroblasts contributing to the development of cardiac fibrosis in vivo (45) . However, a recent study using endothelial lineage tracing in transgenic mice with experimentally-induced renal fibrosis showed that from 10 to 20% of fibroblasts in the fibrotic kidneys arise from endothelial cells via EndoMT (28) in vivo and another study in cardiac fibrosis also showed that a population of cardiac interstitial fibroblasts were of EC origin (46) . 
